Concepedia

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia

Hidenori Arai, Tamio Teramoto, Hiroyuki Daida, Katsunori Ikewaki, Yuko Maeda, Mariko Nakagomi, Masayoshi Shirakawa, Taro Kakikawa, Hirotaka Numaguchi, Amy O. Johnson‐Levonas,

Atherosclerosis · 2016 · 12 citations · 32 references

DOI

Concepts

References

32

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Neil J. Stone, Jennifer G. Robinson, Alice H. Lichtenstein et al. · Circulation · 2013 · 7.1K citations · Full text

, , +15

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Neil J. Stone, Jennifer G. Robinson, Alice H. Lichtenstein et al. · Journal of the American College of Cardiology · 2013 · 3.9K citations · Full text

, , +15

Effects of Torcetrapib in Patients at High Risk for Coronary Events

Philip J. Barter, Mark J. Caulfield, Mats Eriksson et al. · New England Journal of Medicine · 2007 · 3.1K citations · Full text

, , +14

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

Børge G. Nordestgaard, M. John Chapman, Steve E. Humphries et al. · European Heart Journal · 2013 · 2.7K citations · Full text

, , +17

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

Gregory G. Schwartz, Anders Olsson, Markus Abt et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

, , +17